Jul 28, 2022

Featuring an interview with Dr Sandy Srinivas, including the following topics:

• Rationale for and efficacy data from the Phase II SALV-ENZA trial of salvage radiation therapy with enzalutamide or placebo for high-risk recurrent hormone-sensitive prostate cancer (0:00)
• Results from clinical trials evaluating abiraterone, docetaxel or apalutamide for patients with hormone-sensitive prostate cancer (3:29)
• TheraP trial: Three-year overall survival with 177Lu-PSMA-617 versus cabazitaxel for metastatic hormone-resistant prostate cancer (8:31)
• Clinical data with abiraterone acetate in combination with PARP inhibition for patients with metastatic hormone-resistant prostate cancer: Results from the PROpel and MAGNITUDE trials (13:54)
• Current role of neoadjuvant chemotherapy with immunotherapy for patients with metastatic urothelial bladder cancer (UBC); updated long-term outcomes with enfortumab vedotin from the EV-301 trial (20:23)
• Clinical pearls for preventing and managing adverse events with erdafitinib, sacituzumab govitecan or enfortumab vedotin in patients with UBC (25:23)
• HER2 expression in UBC and emerging data with the novel HER2-targeted antibody-drug conjugate RC48 alone and in combination with toripalimab; tolerability of antibody-drug conjugates (30:53)
• Follow-up efficacy and safety data from the KEYNOTE-564 trial; practical implications of the safety data with adjuvant pembrolizumab for renal cell carcinoma (RCC) (36:16)
• Emerging data with the novel agent belzutifan for advanced clear cell RCC (40:11)
• Current practice and potential advances in the first-line treatment of metastatic RCC (44:25)

CME information and select publications